Both bullous pemphigoid and mucous membrane pemphigoid are autoimmune bullous diseases
that can be challenging to treat in individual cases. Janus kinase inhibitors have
shown efficacy in several autoimmune and inflammatory diseases, although these drugs
are not yet widely used in autoimmune bullous diseases. We report two recalcitrant
cases of pemphigoid with mucous membrane involvement which were successfully treated
with the JAK 1/2 inhibitor baricitinib after all other feasible therapeutic options
had been exhausted.
